Form 4: Myriad Genetics CEO Samraat S. Raha Awarded Performance-Based Restricted Stock Units

Myriad Genetics CEO Samraat S. Raha was granted 141,050 performance-based restricted stock units (PSUs) tied to the company's stock price performance.

Summary

• Samraat S. Raha, the President and CEO of Myriad Genetics Inc., was granted 141,050 performance-based restricted stock units (PSUs) on April 30, 2025.
• These PSUs are contingent upon Myriad Genetics achieving specific stock price milestones.
• The Compensation and Human Capital Committee must certify the achievement of these milestones for the PSUs to vest.
• Vesting will occur in four tranches, with 25% of the shares vesting upon the achievement of each stock price milestone.
• No portion of the PSUs may vest earlier than April 30, 2026, and vesting is subject to Raha's continued employment or service.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting a transaction. However, the use of performance-based compensation is generally viewed positively as it aligns management interests with shareholder value. A score of 7 reflects this slightly positive sentiment.

Positives

• The performance-based nature of the stock units aligns executive compensation with the company's stock price performance, incentivizing value creation for shareholders.
• The staggered vesting schedule and continued employment requirement encourage long-term commitment from the CEO.

Risks

• The PSUs may not vest if the company fails to achieve the specified stock price milestones.
• The value of the PSUs is dependent on the future stock price of Myriad Genetics, which is subject to market fluctuations and company performance.

Future Outlook

The vesting of the PSUs is contingent on the future stock price performance of Myriad Genetics.

Industry Context

Performance-based compensation is a common practice in the biotechnology industry to align executive incentives with shareholder value. The specific stock price milestones and vesting schedule would be tailored to Myriad Genetics' strategic goals and market conditions.

Comparison to Industry Standards

• Many biotechnology companies use performance-based equity awards to incentivize executives.
• Companies like Illumina, Thermo Fisher Scientific, and Danaher also utilize similar compensation structures tied to financial and operational metrics.
• The specific stock price milestones for Myriad Genetics would need to be compared to its peers to assess the difficulty and potential reward.

Stakeholder Impact

• Shareholders: The performance-based compensation structure aims to align management's interests with shareholder value creation.
• Employees: The CEO's incentives are tied to the company's overall success, which can positively impact employee morale and performance.

Next Steps

• The Compensation and Human Capital Committee will need to certify the achievement of the stock price milestones.
• The PSUs will vest according to the schedule outlined in the agreement, subject to continued employment.

Key Dates

Keywords

Myriad Genetics, Samraat S. Raha, Performance-Based Restricted Stock Units, PSUs, Stock Price Milestones, Executive Compensation, Vesting, Form 4